These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 33393332)

  • 41. Comparison of short- and long-term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor therapy.
    Manlay L; Boschetti G; Pereira B; Flourié B; Dapoigny M; Reymond M; Sollelis E; Gay C; Boube M; Buisson A; Nancey S
    Aliment Pharmacol Ther; 2021 Jun; 53(12):1289-1299. PubMed ID: 33909920
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pretreatment serum monocyte chemoattractant protein-1 as a predictor of long-term outcome by ustekinumab in patients with Crohn's disease.
    Okuda H; Hosomi S; Itani S; Kurimoto N; Kobayashi Y; Nakata R; Nishida Y; Ominami M; Nadatani Y; Fukunaga S; Otani K; Kamata N; Tanaka F; Nagami Y; Taira K; Ohfuji S; Fujiwara Y
    J Gastroenterol Hepatol; 2023 Jun; 38(6):910-920. PubMed ID: 36807301
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term real-world data of ustekinumab in Crohn's disease: the Stockholm ustekinumab study.
    Bello F; Muhsen S; Sabhan H; Borin A; Johansson F; Höög C; Forsberg O; Wennerström C; Söderman C; Lördal M; Almer S
    Therap Adv Gastroenterol; 2024; 17():17562848241242700. PubMed ID: 38655034
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Predictors of Ustekinumab Failure in Crohn's Disease After Dose Intensification.
    Dalal RS; Njie C; Marcus J; Gupta S; Allegretti JR
    Inflamm Bowel Dis; 2021 Jul; 27(8):1294-1301. PubMed ID: 33146703
    [TBL] [Abstract][Full Text] [Related]  

  • 45. USTEKINUMAB IN CROHN'S DISEASE MANAGEMENT: A BRAZILIAN OBSERVATIONAL STUDY.
    Castro PCS; Magro DO; Nones RB; Furlan TK; Miranda EF; Kotze PG
    Arq Gastroenterol; 2022; 59(4):501-507. PubMed ID: 36515346
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors.
    Onali S; Pugliese D; Caprioli FA; Orlando A; Biancone L; Nardone OM; Imperatore N; Fiorino G; Cappello M; Viola A; Principi MB; Bezzio C; Aratari A; Carparelli S; Mazzuoli S; Manguso F; Grossi L; Bodini G; Ribaldone D; Mocci G; Miranda A; Minerba L; Favale A; Grova M; Scucchi L; Segato S; Fries W; Castiglione F; Armuzzi A; Fantini MC;
    Am J Gastroenterol; 2022 Aug; 117(8):1279-1287. PubMed ID: 35467558
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti-TNF-refractory Crohn's disease.
    Townsend T; Razanskaite V; Dodd S; Storey D; Michail S; Morgan J; Davies M; Penman D; Watters C; Swaminathan M; Sabine J; Chapman A; Smith PJ; Flanagan PK; Reilly I; Bodger K; Subramanian S
    Aliment Pharmacol Ther; 2020 Oct; 52(8):1341-1352. PubMed ID: 32955122
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Predictive factors of the clinical efficacy of ustekinumab in patients with refractory Crohn's disease: tertiary centers experience in Japan.
    Esaki M; Ihara Y; Tominaga N; Takedomi H; Tsuruoka N; Akutagawa T; Yukimoto T; Kawasaki K; Umeno J; Torisu T; Sakata Y
    Int J Colorectal Dis; 2023 Mar; 38(1):57. PubMed ID: 36856849
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates.
    Verstockt B; Dreesen E; Noman M; Outtier A; Van den Berghe N; Aerden I; Compernolle G; Van Assche G; Gils A; Vermeire S; Ferrante M
    J Crohns Colitis; 2019 Jul; 13(7):864-872. PubMed ID: 30715258
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy of ustekinumab in the treatment of patients with Crohn's disease with failure to previous conventional or biologic therapy: a prospective observational real-life study.
    Miranda A; Gravina AG; Cuomo A; Mucherino C; Sgambato D; Facchiano A; Granata L; Priadko K; Pellegrino R; de Filippo FR; Camera S; Cuomo R; Melina R; D'Onofrio V; Manguso F; Ciacci C; Romano M
    J Physiol Pharmacol; 2021 Aug; 72(4):. PubMed ID: 34987127
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Delayed Ustekinumab and Adalimumab Responders Have Similar Outcomes as Early Responders in Biologic-Naïve Crohn's Disease.
    Narula N; Wong ECL; Dulai PS; Marshall JK; Jairath V; Reinisch W
    Am J Gastroenterol; 2024 Jul; 119(7):1355-1364. PubMed ID: 38235763
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effectiveness of swapping to ustekinumab after vedolizumab failure in patients with multi-refractory Crohn's disease.
    Melotti L; Dussias NK; Salice M; Calabrese C; Baldoni M; Scaioli E; Belluzzi A; Mazzotta E; Gionchetti P; Rizzello F
    Dig Liver Dis; 2023 Feb; 55(2):230-234. PubMed ID: 35879185
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term effectiveness and safety of ustekinumab in bio-naïve and bio-experienced anti-tumor necrosis factor patients with Crohn's disease: a real-world multicenter Brazilian study.
    Parra RS; Chebli JMF; Queiroz NSF; Damião AOMC; de Azevedo MFC; Chebli LA; Bertges ER; Alves Junior AJT; Ambrogini Junior O; da Silva BLPS; Lubini M; Bafutto M; Flores C; Vilela EG; Boratto SF; Gasparetti Junior NLT; Steinwurz F; Carvalho NS; Féres O; da Rocha JJR
    BMC Gastroenterol; 2022 Apr; 22(1):199. PubMed ID: 35448949
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effectiveness of ustekinumab in patients with refractory Crohn's disease: a multicentre real-life study in Italy.
    Scribano ML; Aratari A; Neri B; Bezzio C; Balestrieri P; Baccolini V; Falasco G; Camastra C; Pantanella P; Monterubbianesi R; Tullio A; Saibeni S; Papi C; Biancone L; Cosintino R; Faggiani R
    Therap Adv Gastroenterol; 2022; 15():17562848211072412. PubMed ID: 35186121
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Predictors and Outcomes of Ustekinumab Dose Intensification in Ulcerative Colitis: A Multicenter Cohort Study.
    Dalal RS; Esckilsen S; Barnes EL; Pruce JC; Marcus J; Allegretti JR
    Clin Gastroenterol Hepatol; 2022 Oct; 20(10):2399-2401.e4. PubMed ID: 33775893
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab.
    Hu A; Kotze PG; Burgevin A; Tan W; Jess A; Li PS; Kroeker K; Halloran B; Panaccione R; Peyrin-Biroulet L; Ma C; Ananthakrishnan AN
    Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1366-1376.e2. PubMed ID: 32668338
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Real-world effectiveness and safety of ustekinumab in bio-naive patients with moderate-to-severe Crohn's disease: A Canadian multi-center study.
    Bessissow T; Narula N; Ma C; In TSH; Eberg M; Karra K; Jairath V;
    Dig Liver Dis; 2024 Jan; 56(1):61-69. PubMed ID: 37716860
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn's disease: a Chinese real-world study.
    Yao JY; Zhang M; Wang W; Peng X; Zhao JZ; Liu T; Li ZW; Sun HT; Hu P; Zhi M
    BMC Gastroenterol; 2021 Oct; 21(1):380. PubMed ID: 34663208
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn's Disease.
    Straatmijer T; Biemans VBC; Moes DJAR; Hoentjen F; Ter Heine R; Maljaars PWJ; Theeuwen R; Pierik M; Duijvestein M; van der Meulen-de Jong AE;
    Dig Dis Sci; 2023 Jun; 68(6):2647-2657. PubMed ID: 36920666
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy.
    Bermejo F; Jiménez L; Algaba A; Vela M; Bastida G; Merino O; López-García A; Melcarne L; Rodríguez-Lago I; de la Maza S; Bouhmidi A; Barreiro-de Acosta M; López-Serrano P; Carrillo-Palau M; Mesonero F; Orts B; Bonillo D; Granja A; Guerra I
    Inflamm Bowel Dis; 2022 Jan; 28(1):41-47. PubMed ID: 33528018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.